North Korea vs Zimbabwe: Share of the population with anemia in higher risk groups
North Korea
27.5%
in 2023
Zimbabwe
27.5%
in 2023
North Korea rank
83rd
Zimbabwe rank
83rd
Share of the population with anemia in higher risk groups over time
- North Korea
- Zimbabwe
How they compare
North Korea currently reports 27.5% against 27.5% in Zimbabwe, a difference of 0.0%.
The two have swapped places 2 times across 24 shared years of data; in 2000 it was Zimbabwe ahead.
North Korea ranks 83rd and Zimbabwe ranks 83rd of 192 countries.
Across the 3 decades both report, North Korea averaged higher in 2 and Zimbabwe in 1.
Head to head by decade
| Decade | North Korea | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 29.6% | 30.3% | 0.6% | Zimbabwe |
| 2010s | 27.7% | 25.4% | 2.3% | North Korea |
| 2020s | 27.2% | 26.4% | 0.8% | North Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population with anemia in higher risk groups, North Korea or Zimbabwe?
- North Korea, at 27.5% against 27.5% in Zimbabwe as of 2023.
- What is the difference in share of the population with anemia in higher risk groups between North Korea and Zimbabwe?
- 0.0%, with North Korea ahead.
- How many years of comparable data are there for North Korea and Zimbabwe?
- 24 years are reported by both, from 2000 to 2023.
- How do North Korea and Zimbabwe rank globally for share of the population with anemia in higher risk groups?
- North Korea ranks 83rd and Zimbabwe ranks 83rd of 192 countries.
- Where does this data come from?
- Global Health Observatory / World Health Statistics - World Health Organization (WHO), via World Bank (2026) – processed by Our World in Data, published as Share of the population with anemia in higher risk groups. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Anemia is a condition that develops when your blood lacks enough healthy red blood cells or hemoglobin.